• Das Diabetes Magazin
  • Datenschutz
  • Impressum
  • Kontakt
Sonntag, Januar 24, 2021
Gartenfreunde
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
Keine Suchergebnisse
Alle Suchergebnisse einsehen
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
Keine Suchergebnisse
Alle Suchergebnisse einsehen
Diabetes was nun?
Keine Suchergebnisse
Alle Suchergebnisse einsehen

Startseite » Allgemein » CANKADO’s Companion-APP Solution provides Drug-Optimised Digital Applications for Pharmaceutical Companies

CANKADO’s Companion-APP Solution provides Drug-Optimised Digital Applications for Pharmaceutical Companies

17. Dezember 2020
in Allgemein
Minuten Lesezeit2 min
CANKADO
Share on FacebookShare on Twitter

The tool is a drug tailored extension of CANKADO’s e-Health solution

CANKADO’s Companion-APP, the drug-optimised digital application for Pharma companies

Cologne, Germany, 17.12.2020 – CANKADO’s Companion-APP solution provides an environment that helps to build a drug-tailored digital connected care solution for physicians and their patients. Pharmaceutical companies can easily develop their own multi-dimensional drug-optimized digital support for every drug and treatment. It improves patient safety, increases patient compliance, and prolongs drug adherence for a better outcome.

CANKADO Companion-APP is a complete solution comprising a family of medical devices according to EU and US regulations. It is built on CANKADO’s backbone structure that consists of patient’s records ensuring data security and privacy. It allows connection to healthcare professionals and includes the AI-driven PRO-React framework. Information extensions are integrated on Companion-APP, tailored for each drug/treatment. Pharma partners of CANKADO can build their own drug tailored content management system (CMS) using leading-edge technologies. The CANKADO Companion-APP solution provides a simple, fast, and high-value path for joint development. Through the integral development of a large bundle of Companion-APPs, synergistic effects will improve time to market and reduce development and certification costs.

Celgene GmbH, a subsidiary of Bristol Myers Squibb, has signed a contract with CANKADO to accompany all their drugs in hematology for the German market. The first supported drugs will be Revlimid, Luspatercept, and Imnovid.

Companion-APP of CANKADO supports physicians and patients effectively during the treatment phase. CANKADO’s Companion-APP is developed based on extensive knowledge and evidence. CANKADO is a constantly evolving system with a continuous development plan.

CANKADO is a digital health platform with a web/app multilingual system. It is registered as a medical device in the European Union and compliant with the FDA classification for Mobile Medical Devices. CANKADO offers digital health solutions and develops new tools specific to the requirements and outputs of each project. It runs with a wide range of clientele that mostly covers pharmaceutical companies and Clinical Research Organisations (CROs). Click here to enquire further information regarding CANKADO’s digital health services.

CANKADO Service GmbH, headquartered in Germany, operates with over 50 employees with six offices in four countries and has project experience on all continents. CANKADO is the worldwide leading system for multi-lingual support of patients with chronic diseases in routine care and in clinical trials, also offering various digital health solutions in the areas of cancer, diabetes, cardiology, surgery, cell therapy, psychology, and nutrition.

  • 0933 Cologne

    https://partners.cankado.com/

  • 0933 Cologne

    https://www.linkedin.com/company/cankado/

Vorherige News

Die CANKADO Companion-APP: eine für Arzneimittel optimierte, digitale Anwendung für Pharmaunternehmen

Nächste News

CANKADOs e-Health-System unterstützt die neue klinische Prüfung ADAPTlate

Ähnliche Beiträge

Adipositas: wie das Gehirn den Stoffwechsel beeinflusst
Allgemein

Adipositas: wie das Gehirn den Stoffwechsel beeinflusst

14. Januar 2021
CANKADO
Allgemein

CANKADO’s Digital Health Solution Assists a New Clinical Trial, ADAPTlate

7. Januar 2021
CANKADOs e-Health-System unterstützt die neue klinische Prüfung ADAPTlate
Allgemein

CANKADOs e-Health-System unterstützt die neue klinische Prüfung ADAPTlate

7. Januar 2021
Die CANKADO Companion-APP: eine für Arzneimittel optimierte, digitale Anwendung für Pharmaunternehmen
Allgemein

Die CANKADO Companion-APP: eine für Arzneimittel optimierte, digitale Anwendung für Pharmaunternehmen

17. Dezember 2020

Beliebte News

  • COVID-19: Das Wunder von Elgg oder 2 Covid Wellen im Altenheim ohne Tote

    COVID-19: Das Wunder von Elgg oder 2 Covid Wellen im Altenheim ohne Tote

    0 shares
    Share 0 Tweet 0
  • Covid-19: Antrag zur Empfehlung von Vitamin-D Einnahme im Bundestag abgelehnt.

    0 shares
    Share 0 Tweet 0
  • Rauchentwöhnung: So werden Sie rauchfrei

    0 shares
    Share 0 Tweet 0
  • SUBSTANTIAL EXPANSION OF CANKADO’s DIGITAL HEALTH SOLUTION

    0 shares
    Share 0 Tweet 0
  • Ernährung als Medizin – geht das?

    0 shares
    Share 0 Tweet 0
  • Impressum
  • Datenschutz
  • Kontakt
© 2020 Diabetes-Wasnun.de
Keine Suchergebnisse
Alle Suchergebnisse einsehen
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes